# Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

> **NCT02640092** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]GTP1

## Key facts

- **NCT ID:** NCT02640092
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-06-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640092, "Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02640092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*